Testing effectiveness (Phase 2)Study completedNCT01396382What this trial is testing68Ga-DOTATATE PET Scan in Neuroendocrine CancerWho this might be right forNeuroendocrine Carcinoma Vanderbilt-Ingram Cancer Center 97
Testing effectiveness (Phase 2)Study completedNCT01229943What this trial is testingEverolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by SurgeryWho this might be right forAdvanced Pancreatic Neuroendocrine TumorLocally Advanced Pancreatic Neuroendocrine TumorPancreatic Gastrinoma+3 more National Cancer Institute (NCI) 150
Early research (Phase 1)Study completedNCT03849469What this trial is testingXmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsWho this might be right forMelanomaCervical CarcinomaPancreatic Carcinoma+20 more Xencor, Inc. 78
Early research (Phase 1)Ended earlyNCT05831995What this trial is testingSafety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.Who this might be right forAdvanced Solid TumorRAS MutationRAF Mutation+1 more ABM Therapeutics Corporation 12
Not applicableLooking for participantsNCT03787056What this trial is testingPredictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsWho this might be right forCancerBreast CancerGastric Cancer+14 more Hospices Civils de Lyon 410
Testing effectiveness (Phase 2)Looking for participantsNCT05040360What this trial is testingTesting the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsWho this might be right forMetastatic Malignant Neoplasm in the LiverPancreatic Neuroendocrine TumorStage I Pancreatic Neuroendocrine Tumor AJCC v8+2 more SWOG Cancer Research Network 141
Not applicableEnded earlyNCT03407040What this trial is testingGeneration of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapyWho this might be right forGastrointestinal CancersBreast CancerPancreatic Cancer+2 more National Cancer Institute (NCI) 98
Testing effectiveness (Phase 2)Temporarily pausedNCT06202066What this trial is testingTemozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasWho this might be right forDigestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid Neoplasm+1 more Roswell Park Cancer Institute 60
Not applicableLooking for participantsNCT04282083What this trial is testingProtocol ITANET - RegistryWho this might be right forGastro-entero Pancreatic Neuroendocrine Tumors Italian Association Neuroendocrine Tumors 3,600
Not applicableEnrolling By InvitationNCT05600933What this trial is testingProspective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentWho this might be right forSolid TumorsHematologic MalignancyGastrointestinal Cancer+5 more National Cancer Institute (NCI) 1,200
Early research (Phase 1)Study completedNCT02791334What this trial is testingAnti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsWho this might be right forSolid TumorMicrosatellite Instability-High (MSI-H) Solid TumorsCutaneous Melanoma+2 more Eli Lilly and Company 164
Not applicableUnknownNCT03517332What this trial is testingCirculating Tumor DNA Exposure in Peripheral BloodWho this might be right forColorectal CancerPancreatic AdenocarcinomaGastric Cancer+8 more Quantgene Inc. 10,000
Not applicableEnded earlyNCT04106167What this trial is testingLong-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyWho this might be right forAdvanced Solid TumorLymphomaGastric Cancer+15 more Fate Therapeutics 20
Early research (Phase 1)Study completedNCT00073944What this trial is testingBCX-1777 in Treating Patients With Refractory CancerWho this might be right forCancer BioCryst Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02575300What this trial is testingPhase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsWho this might be right forCarcinoid TumorsPancreatic NET H. Lee Moffitt Cancer Center and Research Institute 20
Not applicableStudy completedNCT01135849What this trial is testingB-Receptor Signaling in CardiomyopathyWho this might be right forCarcinomasAmyloidosisAnal Cancer+35 more Daniel Bernstein 99
Testing effectiveness (Phase 2)UnknownNCT02038738What this trial is testing68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine TumorsWho this might be right forNeuroendocrineNeuroendocrine TumorNeuroendocrine Cancer+5 more Ochsner Health System 250
Not applicableActive Not RecruitingNCT00835133What this trial is testingCollecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and MelanomaWho this might be right forFamilial Pancreatic Cancer Mayo Clinic 1,122
Early research (Phase 1)Study completedNCT00006368What this trial is testingYttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerWho this might be right forBrain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT04068896What this trial is testingStudy of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyWho this might be right forPancreatic CancerMetastatic Castration-resistant Prostate CancerBladder Cancer+8 more NGM Biopharmaceuticals, Inc 89